DexcomDXCMEarnings & Financial Report
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
DXCM Q1 FY2026 Key Financial Metrics
Revenue
$1.3B
Gross Profit
$792.7M
Operating Profit
$323.0M
Net Profit
$267.3M
Gross Margin
62.9%
Operating Margin
25.6%
Net Margin
21.2%
YoY Growth
21.6%
EPS
$0.67
Dexcom Q1 FY2026 Financial Summary
Dexcom reported revenue of $1.3B (up 21.6% YoY) for Q1 FY2026, with a net profit of $267.3M (up 153.6% YoY) (21.2% margin). Cost of goods sold was $466.9M, operating expenses totaled $469.7M.
Key Financial Metrics
| Total Revenue | $1.3B |
|---|---|
| Net Profit | $267.3M |
| Gross Margin | 62.9% |
| Operating Margin | 25.6% |
| Report Period | Q1 FY2026 |
Dexcom Annual Revenue by Year
Dexcom annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.7B).
Dexcom Quarterly Revenue & Net Profit History
Dexcom results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $1.3B | +21.6% | $267.3M | 21.2% |
| Q4 FY2025 | $1.3B | +13.1% | $267.3M | 21.2% |
| Q3 FY2025 | $1.2B | +21.6% | $283.8M | 23.5% |
| Q2 FY2025 | $1.2B | +15.2% | $179.8M | 15.5% |
| Q1 FY2025 | $1.0B | +12.5% | $105.4M | 10.2% |
| Q4 FY2024 | $1.1B | +7.6% | $151.7M | 13.6% |
| Q3 FY2024 | $994.2M | +2.0% | $134.6M | 13.5% |
| Q2 FY2024 | $1.0B | +15.3% | $143.5M | 14.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $994.2M | $1.11B | $1.04B | $1.16B | $1.21B | $1.26B | $1.26B |
| YoY Growth | 15.3% | 2.0% | 7.6% | 12.5% | 15.2% | 21.6% | 13.1% | 21.6% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.80B | $6.35B | $6.48B | $6.75B | $7.33B | $7.50B | $6.34B | $6.34B |
| Liabilities | $4.36B | $4.37B | $4.38B | $4.49B | $4.75B | $4.77B | $3.59B | $3.59B |
| Equity | $2.43B | $1.98B | $2.10B | $2.27B | $2.57B | $2.73B | $2.75B | $2.75B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $279.4M | $199.5M | $301.4M | $183.8M | $303.0M | $659.9M | $294.0M |